title: Ngā maihi o Te Whare Hukahuka, ngā maihi o Te Whare o Ruamano: Te whare kōrero o ngā maihi o Tuteao

authors: Hona, Hakahaka Charlie Barlow

subjects: Tuteao

abstract: Ko Pūtauaki te maunga
Ko Rangitāiki te awa
Ko Hekerangi te papa whenua
Ko Tuteao te marae
Ko Ngā Maihi te hapū
Ko Ngāti Awa te iwi
Ko Mataatua te waka
Tihe mauri-ora
Ko tōku kāwai rangatira tēnei. E mōhio ai te tangata ko wai ahau; nō hea ahau, nā wai hoki ahau. Ā, nā whai anō taku urupounamu, ko wai a Ngā Maihi o Tuteao? E mea ana ngā pākeke, he iwi tawhito a Ngā Maihi i heke mai i ngā tātai whakapapa o Tangaroa, o Pōtiki, o Mahutapoanui, o Toroa, o Tuteao. Hēoi, kua kore e rangona ōna kōrero i runga marae ātea. Kua kore e wānangahia i roto i te poho o te whare o Tuteao. Kua ngū ngā poupou o te whare kōrero. Ka mutu, i roto i ngā tau tata nei kua riro tītapu ngā puna o te kī, ngā whītiki o te kupu, o te hapū; kua kore e rangona ngā kōrero o Ngā Maihi i runga marae ātea. Ko te haumate o te reo i runga o Tuteao tētahi take i pēnei ai. Nō reira, kai te imu te ruhi, kai te imu te ngēngē. E noho pōhara ana a Ngā Maihi ki ngā tāonga o tōna whare kōrero. Hei te tau 2027, ka whakanuia te rautau o te whare tīpuna a Tuteao, ā i tēnei tau tonu 2022, e whai whakaaro ana te hapū ki taua kaupapa otirā ki te hanga whare tīpuna hou; he whare kaitā e uru ai te tokomaha. Nō reira, e whakaaro ana hoki ki ngā kōrero ka whakairohia ki ngā pakitara o te whare. I tēnei tau hoki kua mana te whakaako i ngā kōrero hītori o te Māori i roto i ngā kura, nō reira he aha rā ngā kōrero e wātea ana ki ngā tamariki o ngā kura e pā ana ki a Ngā Maihi? He maramara, he kongakonga, he putunga kōrero e noho marara ana i ngā wāhi tūmatanui. He uaua te kitea o ētahi atu, kei ngā wāhi tūmataiti, pēnei i te Kōti Whenua Māori, i ngā tuhinga ā-whānau, kei ngā pukapuka wānanga o te marae. Nō reira, he uaua te kite atu i tōna whānuitanga, i tōna hohonutanga. Tīmata ake i ngā kohinga kōrero o te hapū tonu o Ngā Maihi, i ōna kaumātua, i ōna wānanga, i ōna whānau. I tua atu i wā te whare pukapuka, kei ngā wāhi tūmataiti ētahi putunga kōrero hei ō mo te whare kōrero o Ngā Maihi o Tuteao. Ka mutu, kei ngā waiata, ngā haka, ngā mōteatea. Kai ngā kōrero hoki o iwi kē, e pā ana ki wō mātou tīpuna. I reira i tōtō mai i te kōrero.

text: Ngā maihi o Te Whare Hukahuka, ngā maihi o Te Whare o Ruamano: Te whare kōrero o ngā maihi o Tuteao Ko Pūtauaki te maunga
Ko Rangitāiki te awa
Ko Hekerangi te papa whenua
Ko Tuteao te marae
Ko Ngā Maihi te hapū
Ko Ngāti Awa te iwi
Ko Mataatua te waka
Tihe mauri-ora
Ko tōku kāwai rangatira tēnei. E mōhio ai te tangata ko wai ahau; nō hea ahau, nā wai hoki ahau. Ā, nā whai anō taku urupounamu, ko wai a Ngā Maihi o Tuteao? E mea ana ngā pākeke, he iwi tawhito a Ngā Maihi i heke mai i ngā tātai whakapapa o Tangaroa, o Pōtiki, o Mahutapoanui, o Toroa, o Tuteao. Hēoi, kua kore e rangona ōna kōrero i runga marae ātea. Kua kore e wānangahia i roto i te poho o te whare o Tuteao. Kua ngū ngā poupou o te whare kōrero. Ka mutu, i roto i ngā tau tata nei kua riro tītapu ngā puna o te kī, ngā whītiki o te kupu, o te hapū; kua kore e rangona ngā kōrero o Ngā Maihi i runga marae ātea. Ko te haumate o te reo i runga o Tuteao tētahi take i pēnei ai. Nō reira, kai te imu te ruhi, kai te imu te ngēngē. E noho pōhara ana a Ngā Maihi ki ngā tāonga o tōna whare kōrero. Hei te tau 2027, ka whakanuia te rautau o te whare tīpuna a Tuteao, ā i tēnei tau tonu 2022, e whai whakaaro ana te hapū ki taua kaupapa otirā ki te hanga whare tīpuna hou; he whare kaitā e uru ai te tokomaha. Nō reira, e whakaaro ana hoki ki ngā kōrero ka whakairohia ki ngā pakitara o te whare. I tēnei tau hoki kua mana te whakaako i ngā kōrero hītori o te Māori i roto i ngā kura, nō reira he aha rā ngā kōrero e wātea ana ki ngā tamariki o ngā kura e pā ana ki a Ngā Maihi? He maramara, he kongakonga, he putunga kōrero e noho marara ana i ngā wāhi tūmatanui. He uaua te kitea o ētahi atu, kei ngā wāhi tūmataiti, pēnei i te Kōti Whenua Māori, i ngā tuhinga ā-whānau, kei ngā pukapuka wānanga o te marae. Nō reira, he uaua te kite atu i tōna whānuitanga, i tōna hohonutanga. Tīmata ake i ngā kohinga kōrero o te hapū tonu o Ngā Maihi, i ōna kaumātua, i ōna wānanga, i ōna whānau. I tua atu i wā te whare pukapuka, kei ngā wāhi tūmataiti ētahi putunga kōrero hei ō mo te whare kōrero o Ngā Maihi o Tuteao. Ka mutu, kei ngā waiata, ngā haka, ngā mōteatea. Kai ngā kōrero hoki o iwi kē, e pā ana ki wō mātou tīpuna. I reira i tōtō mai i te kōrero.

year: 2022

title: Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent?

authors: Lawrenson, Ross

subjects: Lung cancer

abstract: BACKGROUNDS: This study aims to understand the factors that influence whether patients receive potentially curative treatment for early stage lung cancer. A key question was whether indigenous Māori patients were less likely to receive treatment. 
METHODS: Patients included those diagnosed with early stage lung cancer in 2011-2018 and resident in the New Zealand Midland Cancer Network region. Logistic regression model was used to estimate the odds ratios of having curative surgery/ treatment. The Kaplan Meier method was used to examine the all-cause survival and Cox proportional hazard model was used to estimate the hazard ratio of death. 
RESULTS: In total 419/583 (71.9%) of patients with Stage I and II disease were treated with curative intent - 272 (46.7%) patients had curative surgery. Patients not receiving potentially curative treatment were older, were less likely to have non-small cell lung cancer (NSCLC), had poorer lung function and were more likely to have an ECOG performance status of 2+. Current smokers were less likely to be treated with surgery and more likely to receive treatment with radiotherapy and chemotherapy. Those who were treated with surgery had a 2-year survival of 87.8% (95% CI: 83.8-91.8%) and 5-year survival of 69.6% (95% CI: 63.2-76.0%). Stereotactic ablative body radiotherapy (SABR) has equivalent effect on survival compared to curative surgery (hazard ratio: 0.77, 95% CI: 0.37-1.61). After adjustment we could find no difference in treatment and survival between Māori and non-Māori. 
CONCLUSIONS: The majority of patients with stage I and II lung cancer are managed with potentially curative treatment - mainly surgery and increasingly with SABR. The outcomes of those being diagnosed with stage I and II disease and receiving treatment is positive with 70% surviving 5 years.

text: Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent? BACKGROUNDS: This study aims to understand the factors that influence whether patients receive potentially curative treatment for early stage lung cancer. A key question was whether indigenous Māori patients were less likely to receive treatment. 
METHODS: Patients included those diagnosed with early stage lung cancer in 2011-2018 and resident in the New Zealand Midland Cancer Network region. Logistic regression model was used to estimate the odds ratios of having curative surgery/ treatment. The Kaplan Meier method was used to examine the all-cause survival and Cox proportional hazard model was used to estimate the hazard ratio of death. 
RESULTS: In total 419/583 (71.9%) of patients with Stage I and II disease were treated with curative intent - 272 (46.7%) patients had curative surgery. Patients not receiving potentially curative treatment were older, were less likely to have non-small cell lung cancer (NSCLC), had poorer lung function and were more likely to have an ECOG performance status of 2+. Current smokers were less likely to be treated with surgery and more likely to receive treatment with radiotherapy and chemotherapy. Those who were treated with surgery had a 2-year survival of 87.8% (95% CI: 83.8-91.8%) and 5-year survival of 69.6% (95% CI: 63.2-76.0%). Stereotactic ablative body radiotherapy (SABR) has equivalent effect on survival compared to curative surgery (hazard ratio: 0.77, 95% CI: 0.37-1.61). After adjustment we could find no difference in treatment and survival between Māori and non-Māori. 
CONCLUSIONS: The majority of patients with stage I and II lung cancer are managed with potentially curative treatment - mainly surgery and increasingly with SABR. The outcomes of those being diagnosed with stage I and II disease and receiving treatment is positive with 70% surviving 5 years.

year: 2020

title: A mandatory COVID-19 vaccination policy - Is there a place in New Zealand?

authors: Sugimoto, Irene

subjects: COVID-19

abstract: It has been nearly a year and a half since COVID-19 emerged in New Zealand. Although New Zealand has been fortunate enough to have little to no active community cases, it is still enduring the effects of COVID-19. The COVID-19 lockdown measures and continued strict border closures has caused the New Zealand economy as well as the New Zealand population’s mental health to deteriorate. Current COVID-19 management strategies are too costly and are detrimental to New Zealand. Therefore, to minimise the damage caused by COVID-19, it is crucial that New Zealand achieves herd immunity against COVID-19 through vaccinations. However, New Zealand may struggle to reach herd immunity due to the presence of vaccine hesitancy. Accordingly, the New Zealand Government may need to introduce a mandatory COVID-19 vaccination policy to achieve herd immunity.

A mandatory COVID-19 vaccination policy would engage and limit the right to refuse medical treatment which is affirmed under s 11 of the New Zealand Bill of Rights Act. The New Zealand Government would need to ensure that a mandatory COVID-19 vaccination policy is a justified limitation placed upon the s 11 right. To do this, the New Zealand Government must balance the public health interests with the right to personal autonomy. Although New Zealand places a high value on personal autonomy, the New Zealand Government has previously overridden personal autonomy to protect the nation’s health and well-being from public health crises (including COVID-19). Because New Zealand has a precedent of prioritising the population’s well-being over individuals’ rights, it is possible for the New Zealand Government to implement a mandatory COVID-19 vaccination policy. However, to introduce such policy, the New Zealand Government must observe the rule of law to uphold the foundation of a liberal democracy. If the New Zealand Government fails to consider the rule of law, a mandatory COVID-19 vaccination policy can be deemed ultra vires and is likely that public trust and confidence in vaccinations and governments will decline.

In summary, this paper argues that if New Zealand struggles to achieve herd immunity, people who can receive COVID-19 vaccinations should be subject to a mandatory COVID-19 vaccination policy. This is because the right to exercise personal autonomy turns into a privilege from a right if it causes harm upon others. If COVID-19 vaccinations are not mandated, people who actively chose to not be vaccinated will increase the spread of COVID-19 and create significant health risks. One may argue that being vaccinated against COVID-19 comes with the risk of experiencing adverse reactions. However, such risks are small compared to the risk of contracting COVID-19 and are outweighed by the benefits associated with COVID-19 vaccinations.

text: A mandatory COVID-19 vaccination policy - Is there a place in New Zealand? It has been nearly a year and a half since COVID-19 emerged in New Zealand. Although New Zealand has been fortunate enough to have little to no active community cases, it is still enduring the effects of COVID-19. The COVID-19 lockdown measures and continued strict border closures has caused the New Zealand economy as well as the New Zealand population’s mental health to deteriorate. Current COVID-19 management strategies are too costly and are detrimental to New Zealand. Therefore, to minimise the damage caused by COVID-19, it is crucial that New Zealand achieves herd immunity against COVID-19 through vaccinations. However, New Zealand may struggle to reach herd immunity due to the presence of vaccine hesitancy. Accordingly, the New Zealand Government may need to introduce a mandatory COVID-19 vaccination policy to achieve herd immunity.

A mandatory COVID-19 vaccination policy would engage and limit the right to refuse medical treatment which is affirmed under s 11 of the New Zealand Bill of Rights Act. The New Zealand Government would need to ensure that a mandatory COVID-19 vaccination policy is a justified limitation placed upon the s 11 right. To do this, the New Zealand Government must balance the public health interests with the right to personal autonomy. Although New Zealand places a high value on personal autonomy, the New Zealand Government has previously overridden personal autonomy to protect the nation’s health and well-being from public health crises (including COVID-19). Because New Zealand has a precedent of prioritising the population’s well-being over individuals’ rights, it is possible for the New Zealand Government to implement a mandatory COVID-19 vaccination policy. However, to introduce such policy, the New Zealand Government must observe the rule of law to uphold the foundation of a liberal democracy. If the New Zealand Government fails to consider the rule of law, a mandatory COVID-19 vaccination policy can be deemed ultra vires and is likely that public trust and confidence in vaccinations and governments will decline.

In summary, this paper argues that if New Zealand struggles to achieve herd immunity, people who can receive COVID-19 vaccinations should be subject to a mandatory COVID-19 vaccination policy. This is because the right to exercise personal autonomy turns into a privilege from a right if it causes harm upon others. If COVID-19 vaccinations are not mandated, people who actively chose to not be vaccinated will increase the spread of COVID-19 and create significant health risks. One may argue that being vaccinated against COVID-19 comes with the risk of experiencing adverse reactions. However, such risks are small compared to the risk of contracting COVID-19 and are outweighed by the benefits associated with COVID-19 vaccinations.

year: 2021